ETF Research Center

Global X Telemedicine & Digital Health UCITS ETF

ALTAR
Score™

0.2%

Recommen-
dation

AVOID

2025E 2026E
P/E ratio	53.4x	P/Sales ratio	1.7x
P/BV ratio	3.1x	Div. yield	-0.4%

Description
Performance
Comps
Fundamentals
Valuation
Rating

EDOC invests in companies positioned to benefit from further advances in the field of telemedicine and digital health. This includes companies involved in Telemedicine, Health Care Analytics, Connected Health Care Devices, and Administrative Digitization.

FUND BASICS
Category	Global Equities
Fund Sponsor	Global X
Website
Inception date	Dec 16, 2020
Assets (mns)	$5
Currency	USD
Expense ratio	68 bp
Distributions

FUND STRUCTURE
Regulation	UCITS
Custodian
Weighting	Market Cap
Index replication
Uses derivatives	No
Options available	No

SECTOR BREAKDOWN

CONSTITUENT BREAKDOWN
No. of constituents	39
Wgt avg mkt cap (mns)	$11,024
Large cap (>$10bn)	47.7%
Mid cap ($2-10bn)	31.8%
Small cap (<$2bn)	20.4%
Developed mkts	96.0%
Emerging mkts	4.0%

TOP TEN HOLDINGS
Total	46.1 %
HIMS & HERS HEALTH, INC. CLASS A	6.3 %
PRO MEDICUS LIMITED	5.5 %
IRHYTHM TECHNOLOGIES, INC.	4.7 %
ILLUMINA INC	4.6 %
DEXCOM INC	4.4 %
RESMED INC	4.2 %
INSULET CORP	4.2 %
AGILENT TECHNOLOGIES INC	4.1 %
JD HEALTH INTERNATIONAL, INC.	4.1 %
QIAGEN N.V.	4.0 %

TOP COUNTRY EXPOSURE
	UNITED STATES	75.7 %
	CHINA	5.7 %
	AUSTRALIA	5.5 %
	NETHERLANDS	4.0 %
	HONG KONG	3.2 %
	JAPAN	1.6 %
	SWEDEN	0.5 %

HISTORICAL PERFORMANCE info

	Custom date range	Compare to
	thru

Standardized Annual Returns (thru June 30)
Year-to-date	1 year	5 years	10 years	Since Incep.
10.7%	25.3%	--	--	10.6%

Market Correlations
versus...	Beta	R-squared
S&P500	1.16	54%
MSCI EAFE	0.91	35%
MSCI Emg. Mkts.	0.71	22%

Technical Indicators
Recent close	$8.55
30d moving avg.	$8.45
Annualized volatility	25.5%
Short interest (ETF)	0.0%
Relative strength (RSI)	56

Liquidity measures
Avg. volume (thou.)	1
Turnover	0.2%
Bid/Ask (% of price)	0.00%
ADV underlying (mns)	$1,546

Distributions

There were no matches found with other funds under coverage.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

	2020	2021	2022	2023	2024	2025E	2026E
Sales per share	**	**	**	**	**	**	**
Earnings per share	**	**	**	**	**	**	**
Dividends per share	**	**	**	**	**	**	**
Book value per share	**	**	**	**	**	**	**

Sales per share growth		**%	**%	**%	**%	**%	**%
EPS growth		**%	**%	**%	**%	**%	**%

Sales per share growth		**%	**%	**%	**%	**%	**%
EPS growth		**%	**%	**%	**%	**%	**%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est.	**%		Debt-to-equity	**x
Asset turnover	**%		Assets-to-equity	**x

Return on equity

Revision activity*

*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS

	2024	2025E	2026E
Price-to-sales	**	**	**
Price-to-earnings	**	**	**
Price-to-cash flow	**	**	**
Price-to-growth	**	**	**
Price-to-book value	**	**	**
Yield	**	**	**

Historical valuation trends

Forward multiple:	Global X Telemedicine & Digital Health UCITS ETF
Relative to:	S&P500	MSCI EAFE	MSCI Emg. Mkts.	Other ETF:

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant.

ALTAR Score™

Calculation of ALTAR Score™
Avg. Return on Equity	2.4	%
Divided by: Fwd. P/BV	2.9	x
Less: Expense ratio	68	bp
Equals: ALTAR Score	0.2	%

More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS

COMPOSITE RATING	1.56	CATEGORY AVERAGE	1.57

The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale: BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3. Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.